Search
Sotorasib
go.drugbank.com/drugs/DB15569ApprovedInvestigational[A187547] Sotorasib was granted FDA approval on May 28, 2021,[L34288] followed by the European Commission's approval on January 6, 2022.[L56070] … [A187547,A187556] It is indicated in the treatment of adult patients with KRAS G12C mutant non-small cell lung cancer.[L34288] This mutation makes up >50% of all KRAS mutations.
Products: LUMAKRAS 120 MG FİLM KAPLI TABLET, 240 ADETAncrod
go.drugbank.com/drugs/DB05099ApprovedWithdrawnThe defribrinogenation of blood results in an anticoagulant effect. … FDA granted a 'fast-track status' for investigation of ancrod use in patients suffering from acute ischemic stroke, a life threatening condition caused by the blockage of blood vessels supplying blood
Pasireotide
go.drugbank.com/drugs/DB06663ApprovedInvestigationalIt is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.
Synonyms: cyclo((4R)-4-(2-aminoethylcarbamoyloxy)-L-prolyl-L-phenylglycyl-D-tryptophyl-L-lysyl-4-O-benzyl-L-tyrosyl-L- phenylalanyl-)Products: SIGNIFOR® LAR 20 MG, SIGNIFOR® LAR 40 MGRilonacept
go.drugbank.com/drugs/DB06372ApprovedInvestigationalRilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. … Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome (FCAS)
Olaratumab
go.drugbank.com/drugs/DB06043ApprovedInvestigationalStudies show that the treatment of olaratumab in combination with doxorubicin resulted in significant reduction of cancer cell proliferation and tumor growth. … It is composed of two heavy chain molecule fragments and 2 light chain fragments.
Amiodarone
go.drugbank.com/drugs/DB01118ApprovedInvestigationalAmiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. … Because of its ability to cause serious toxicity and possibly death, amiodarone use should be reserved for its approved indications, according to prescribing information.[L3561,L11265,L11286]
Categories: Metabolic Side Effects of Drugs and SubstancesProducts: Nu-amiodarone, AMIODARONE EGHydroxyurea
go.drugbank.com/drugs/DB01005ApprovedInvestigational[A262601] Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, hydroxyurea is used sparingly in clinical settings, largely due to lack of knowledge and adherence, the … [A262596] It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults.
Products: HYDRINE CAPSULES 500 mg, Litalir 500 mg - KapselnFloxuridine
go.drugbank.com/drugs/DB00322ApprovedInvestigationalIt has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
Odevixibat
go.drugbank.com/drugs/DB16261ApprovedInvestigationalOdevixibat, or A4250, is an ileal sodium/bile acid cotransporter inhibitor indicated for the treatment of pruritus in patients older than 3 months, with progressive familial intrahepatic cholestasis (PFIC … [A236808] Odevixibat was granted FDA and Health Canada approval on 20 July 2021 and 13 November 2023 respectively.[L34793,L49535]
Maralixibat
go.drugbank.com/drugs/DB16226ApprovedInvestigationalIt was granted FDA approval on 29 September 2021. … [A239249] No clinical trials have been performed to assess the efficacy of these treatments for cholestatic pruritus and treatments were given based on a prescriber's clinical experience.